CN105283198A - 作为恶性肿瘤控制中的单一疗法的新型肽 - Google Patents

作为恶性肿瘤控制中的单一疗法的新型肽 Download PDF

Info

Publication number
CN105283198A
CN105283198A CN201380075150.2A CN201380075150A CN105283198A CN 105283198 A CN105283198 A CN 105283198A CN 201380075150 A CN201380075150 A CN 201380075150A CN 105283198 A CN105283198 A CN 105283198A
Authority
CN
China
Prior art keywords
peptides
cancer
control
malignancy
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380075150.2A
Other languages
English (en)
Inventor
卡勒德·莫希·埃尔丹·伊罗丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105283198A publication Critical patent/CN105283198A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

尽管在所有类型的恶性肿瘤控制，如手术、化学疗法、放射疗法和免疫疗法中取得进步，但许多类型的癌症的预后仍极差。只需看看任何一个国家的主要死亡原因，任何人都会知道癌症是其中一种并且发现其治疗中的挑战性和缺陷。许多研究者仅致力于改良现有方法。总之，我认为我们必须引入一些新的事物，而非仅考虑通过改良常规方法来克服这一挑战。尽管市场上存在许多用于恶性肿瘤控制的肽，我们引入具有这些序列(在所有或在一些或类似序列中)的新型肽作为用于癌症控制的单一疗法。我意指不需要除诊断以外的任何常规方法。这些肽中的任一种或超过一种直到全部都具有从N端到C端的这些序列。

Description

作为恶性肿瘤控制中的单一疗法的新型肽
技术领域
作为恶性肿瘤控制中的单一疗法的新型肽。
背景技术
在恶性肿瘤的管理方面，我们具有四种主要手段。
手术：手术可用于预防、治疗、分阶段(确定癌症的发展程度)和诊断癌症。关于癌症治疗，进行手术以切除肿瘤或尽可能多的癌组织。其通常与化学疗法或放射疗法一起进行。
对于那些癌症不可治疗的患者，姑息手术是可以减轻由癌症引起的疼痛的选择方案。姑息手术的目的并不是治疗或治愈癌症，或甚至延长寿命，而更多的是减轻不适感。
化学疗法：化学疗法是一种使用药物消除癌细胞的癌症治疗手段。与手术不同，化学疗法影响整个身体，而不仅仅是特定部分。其通过靶向快速繁殖的癌细胞来发挥作用。不幸的是，我们体内的其它类型的细胞也高速繁殖，如毛囊细胞和使我们胃部顺畅的细胞。这就是为何化疗可引起如脱发和肚子痛等副作用。
化学疗法最常见的施与方式是通过药丸或静脉注射(IV)，但也可以有其他施与方式。单一类型的化学疗法或药物的组合可指定使用特定时间长度。与手术相同，化学疗法可单独、与放射疗法或生物疗法一起开处方。
放射疗法：放射疗法使用某些类型的能量缩小肿瘤或消除癌细胞。其通过破坏癌细胞的DNA，使其不能繁殖来发挥作用。癌细胞对放射高度敏感并且通常在治疗时死亡。附近的健康细胞也可能被破坏，但可复原并且能够完全恢复。
放射疗法可单独施与、与化学疗法和/或手术一起施与。将放射疗法与其它类型的治疗组合的决策取决于癌症的阶段和其它因素。
生物或靶向疗法：
生物疗法是用于靶向癌瘤的特征的药物的术语。一些类型的靶向疗法通过阻断肿瘤的使肿瘤成长和生长的生物过程来发挥作用。其它类型的疗法切断肿瘤的血液供应，使其因为缺少血液而根本上饿死。
靶向疗法用于选定类型的癌症并且不适用于每个人。其与其它癌症治疗一起施与。
问题和缺陷：
尽管存在许多用于管理恶性肿瘤的方法，如手术、化学疗法、放射疗法、免疫疗法等。
许多类型的癌症仍具有极差的预后。
只需看看任何一个国家的主要死亡原因，任何人都会知道癌症是其中一种并且发现其治疗的挑战性和缺陷。
许多研究者仅致力于改良现有方法。
总之，我认为我们必须引入一些新的内容，而非仅考虑改良传统方法来克服这一挑战。
发明内容
我们引入这些肽作为恶性肿瘤控制中的单一疗法：
这些肽中的一种或超过一种直到全部都具有从N端到C端的这些序列。
1-MAILTYVYVFAVLFIANSMQA
2-MAILTYVYVFAVLFIAKKKK
3-MQLRVLFFFLFVATISYAIAD
4-MQLRVLFFFLFVATISKKKKK
5-MQLKALFFLLFAATISKKKKK
6-MTKWLLLVVCLGIACQ
7-MTKWLLLVVCLGIACQKKKKK
因此，我们要求保护这些肽序列，因为这些肽中的一种或更多种可用作癌症控制中的药物。

Claims (2)

1.我们在恶性肿瘤的管理中引入一些与传统方法不同的新内容。
2.我们在恶性肿瘤控制中的新型方法中引入具有某些序列的新型肽作为单一疗法。
这些肽中的任一种或超过一种直到全部都具有从N端到C端的这些序列。
1-MAILTYVYVFAVLFIANSMQA
2-MAILTYVYVFAVLFIAKKKK
3-MQLRVLFFFLFVATISYAIAD
4-MQLRVLFFFLFVATISKKKKK
5-MQLKALFFLLFAATISKKKKK
6-MTKWLLLVVCLGLACQ
7-MTKWLLLVVCLGIACQKKKKK
因此，我们要求保护这些肽序列，因为这些肽中的一种或更多种可用作癌症控制中的药物。
CN201380075150.2A 2013-04-09 2013-04-09 作为恶性肿瘤控制中的单一疗法的新型肽 Pending CN105283198A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EG2013/000008 WO2014040605A1 (en) 2013-04-09 2013-04-09 New peptides as a monotherapy in malignancy control

Publications (1)

Publication Number Publication Date
CN105283198A true CN105283198A (zh) 2016-01-27

Family

ID=48288704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380075150.2A Pending CN105283198A (zh) 2013-04-09 2013-04-09 作为恶性肿瘤控制中的单一疗法的新型肽

Country Status (4)

Country Link
US (1) US20150291663A1 (zh)
JP (1) JP2016518352A (zh)
CN (1) CN105283198A (zh)
WO (1) WO2014040605A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182044A1 (en) 2017-03-05 2017-10-26 Elawadan Khaled Mohy Eldin New modified synthetic peptides derived from honey proteins in cancer control
WO2023001350A1 (en) 2022-03-15 2023-01-26 Elawdan Khaled Mohy Eldin Modified honey related synthetic peptides in cancer control.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541167A1 (en) * 2002-08-29 2005-06-15 Hayashibara, Ken Antiallergic agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001297741A1 (en) * 2000-11-22 2002-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
EP1379265A4 (en) * 2001-03-28 2005-09-14 Helix Biomedix Inc SHORT BIOACTIVE PEPTIDES AND METHODS OF USE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541167A1 (en) * 2002-08-29 2005-06-15 Hayashibara, Ken Antiallergic agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GENBANK: "Q17060", 《GENBANK》 *
GENBANK: "XM_001120220.1", 《GENBANK》 *
GENBANK: "XM_397512.1", 《GENBANK》 *
IWAO OKAMOTO，ET AL.: "Major royal jelly protein 3 modulates immune responses in vitro and in vivo", 《LIFE SCIENCES》 *
NORMAN A. RATCLIFFE, ET AL.: "Insect natural products and processes: New treatments for human disease", 《INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY》 *

Also Published As

Publication number Publication date
JP2016518352A (ja) 2016-06-23
US20150291663A1 (en) 2015-10-15
WO2014040605A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
Pollack et al. Childhood brain tumors: current management, biological insights, and future directions: JNSPG 75th Anniversary Invited Review Article
Lin et al. Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment
WO2015049688A3 (en) Patient-specific immunotherapy for treating heterogeneous tumors
Badakhshi et al. Oligometastases: the new paradigm and options for radiotherapy
Wu et al. Endostar combined with radiotherapy increases radiation sensitivity by decreasing the expression of TGF-β1, HIF-1α and bFGF
CN105283198A (zh) 作为恶性肿瘤控制中的单一疗法的新型肽
Fleischmann et al. Radioimmunotherapy: future prospects from the perspective of brachytherapy
Toms et al. Recent advances in the treatment of gliomas–comprehensive brain tumor center
US20210138053A1 (en) Anti-tumoral composition
Wen Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases
Tsang Nasopharyngeal carcinoma-improving cure with technology and clinical trials
Xu et al. Trastuzumab monotherapy for bone marrow metastasis of breast cancer: a case report
Varol et al. Anticancer therapy for breast cancer patients with skin metastases refractory to conventional treatments
Yang Research progress in diagnosis and management strategies of multiple primary lung cancer
Verstegen et al. Developments in early-stage NSCLC: advances in radiotherapy
Xu et al. The radiation therapy in keloids treatment: a comprehensive review of pathomechanism, damage mechanisms and cellular response
Guo et al. Enhanced electric pulse technology for the ablation of pancreatic cancer
Hu et al. Adjuvant radiotherapy for dermatofibrosarcoma protuberans
Kerna et al. Stereotaktilise kiiritusravi rakendamine oligometastaatilise kasvaja korral
Ou ES18. 04 new strategies to overcome resistance in ALK rearranged NSCLC
Katare et al. Gene therapy for the cancer treatment
Hu et al. Adjuvant radiotherapy for dermatofibrosarcoma protuberans: a case report
Morales et al. Intensity Modulated Radiotherapy (IMRT) in the Planning of Hypofractionated Treatment in Head and Neck Tumors
Hanna IBS19. 02 Novel Radiotherapy Approaches in Small Cell Lung Carcinoma–Has SABR and Radionuclide Therapy Got a Role to Play?
Herrick et al. Cancer as a chronic disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160127

WD01 Invention patent application deemed withdrawn after publication